BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Can Boston Scientific Corporation (BSX) Capitalize on St. Jude Medical (STJ)'s Challenges?


1/10/2013 8:43:41 AM

Boston Scientific CFO Jeffrey Capello says the medical device giant is looking to capitalize on the reliability of its ICD leads, especially in light of the "challenges" faced by an ICD competitor. Boston Scientific (NYSE:BSX) is looking for ways to leverage its product pipeline in 2013, part of which may include capitalizing on some of the "challenges" facing one of their biggest rivals. Neither CEO Michael Mahoney, nor CFO Jeffrey Capello named names during a breakout session following a presentation at the J.P. Morgan Healthcare conference in San Francisco, but its likely the executives were referring to St. Jude Medical (NYSE:STJ), and its ongoing difficulties with their recalled Riata defibrillator leads.

Read at MassDevice

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES